We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Actinium (ATNM) Up on Commercialization Deal With Immedica
Read MoreHide Full Article
Shares of Actinium Pharmaceuticals (ATNM - Free Report) were up 24% on Tuesday after management announced that ATNM has entered into a license and supply agreement with Sweden-based Immedica BioPharma for its most advanced pipeline candidate.
Per the terms of the agreement, Actinium granted exclusive rights for Iomab-B, its investigational antibody radiation conjugate (ARC), to Immedica in Europe, the Middle East and North Africa. In return, ATNM will receive an upfront payment of $35 million from Immedica. In addition, ATNM is eligible to receive milestone payments up to $417 million as well as future royalties on the product’s net sales in the above-mentioned markets. However, ATNM will remain responsible for certain clinical and regulatory activities as well as manufacturing Iomab-B in the aforementioned regions.
Actinium developed Iomab-B for targeted conditioning to facilitate bone marrow transplant (BMT). ATNM is currently evaluating this candidate in the pivotal phase III SIERRA study against physician’s choice of salvage therapy in elderly patients (aged 55 years and older) with relapsed or refractory (r/r) acute myeloid leukemia (AML). Topline data from the SIERRA study is anticipated in third-quarter 2022.
Shares of Actinium have gained 9.2% so far this year against the industry’s 16.2% decrease.
Image Source: Zacks Investment Research
Currently, BMT is the only potentially curative treatment option to certain blood-borne cancers including r/r AML. Per management, Iomab-B provides a safer treatment option to patients preparing for BMT conditioning by avoiding the side-effects of non-targeted intensive chemotherapy, the current standard of care for conditioning BMT, on healthy tissues and at the same time, effectively killing a patient’s cancer cells. Notably, Iomab-B is already granted orphan drug designations in the United States and the European Union (EU).
With no marketed products in its portfolio, ATNM is highly dependent on its ARC pipeline for growth. Although Actinium has multiple candidates in its pipeline, most are in early-stage development and still years away from a potential approval and commercialization. Positive data from the SIERRA study will enable ATNM to proceed for a potential approval of Iomab-B for BMT conditioning in AML patients.
Actinium presently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the overall healthcare sector are Angion Biomedica , Assertio Holdings (ASRT - Free Report) and Collegium Pharmaceutical (COLL - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Angion Biomedica’s loss per share estimates for 2022 have narrowed from $2.52 to $1.92 in the past 60 days. The same for 2023 has narrowed from $3.11 to $2.19 in the past 60 days.
Earnings of Angion Biomedica beat estimates in three of the last four quarters and missed the mark once, the average surprise being 47.5%.
Assertio Holdings’ earnings per share estimates for 2022 have increased from 20 cents to 35 cents in the past 60 days. Shares of ASRT have rallied 40.4% in the year-to-date period.
Earnings of Assertio Holdings beat estimates in two of the last four quarters and missed the mark in the other two, the average surprise being 20.8%.
Collegium Pharmaceutical’s earnings per share estimates for 2022 have increased from $3.79 to $5.59 in the past 60 days. The same for 2023 has increased from $4.79 to $7.44 in the past 60 days. Shares of COLL have risen 3.1% year to date.
Earnings of Collegium Pharmaceutical missed estimates in three of the last four quarters and beat the mark on one occasion, the negative surprise being 57.6%, on average.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Actinium (ATNM) Up on Commercialization Deal With Immedica
Shares of Actinium Pharmaceuticals (ATNM - Free Report) were up 24% on Tuesday after management announced that ATNM has entered into a license and supply agreement with Sweden-based Immedica BioPharma for its most advanced pipeline candidate.
Per the terms of the agreement, Actinium granted exclusive rights for Iomab-B, its investigational antibody radiation conjugate (ARC), to Immedica in Europe, the Middle East and North Africa. In return, ATNM will receive an upfront payment of $35 million from Immedica. In addition, ATNM is eligible to receive milestone payments up to $417 million as well as future royalties on the product’s net sales in the above-mentioned markets. However, ATNM will remain responsible for certain clinical and regulatory activities as well as manufacturing Iomab-B in the aforementioned regions.
Actinium developed Iomab-B for targeted conditioning to facilitate bone marrow transplant (BMT). ATNM is currently evaluating this candidate in the pivotal phase III SIERRA study against physician’s choice of salvage therapy in elderly patients (aged 55 years and older) with relapsed or refractory (r/r) acute myeloid leukemia (AML). Topline data from the SIERRA study is anticipated in third-quarter 2022.
Shares of Actinium have gained 9.2% so far this year against the industry’s 16.2% decrease.
Image Source: Zacks Investment Research
Currently, BMT is the only potentially curative treatment option to certain blood-borne cancers including r/r AML. Per management, Iomab-B provides a safer treatment option to patients preparing for BMT conditioning by avoiding the side-effects of non-targeted intensive chemotherapy, the current standard of care for conditioning BMT, on healthy tissues and at the same time, effectively killing a patient’s cancer cells. Notably, Iomab-B is already granted orphan drug designations in the United States and the European Union (EU).
With no marketed products in its portfolio, ATNM is highly dependent on its ARC pipeline for growth. Although Actinium has multiple candidates in its pipeline, most are in early-stage development and still years away from a potential approval and commercialization. Positive data from the SIERRA study will enable ATNM to proceed for a potential approval of Iomab-B for BMT conditioning in AML patients.
Actinium Pharmaceuticals, Inc. Price
Actinium Pharmaceuticals, Inc. price | Actinium Pharmaceuticals, Inc. Quote
Zacks Rank & Key Picks
Actinium presently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the overall healthcare sector are Angion Biomedica , Assertio Holdings (ASRT - Free Report) and Collegium Pharmaceutical (COLL - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
Angion Biomedica’s loss per share estimates for 2022 have narrowed from $2.52 to $1.92 in the past 60 days. The same for 2023 has narrowed from $3.11 to $2.19 in the past 60 days.
Earnings of Angion Biomedica beat estimates in three of the last four quarters and missed the mark once, the average surprise being 47.5%.
Assertio Holdings’ earnings per share estimates for 2022 have increased from 20 cents to 35 cents in the past 60 days. Shares of ASRT have rallied 40.4% in the year-to-date period.
Earnings of Assertio Holdings beat estimates in two of the last four quarters and missed the mark in the other two, the average surprise being 20.8%.
Collegium Pharmaceutical’s earnings per share estimates for 2022 have increased from $3.79 to $5.59 in the past 60 days. The same for 2023 has increased from $4.79 to $7.44 in the past 60 days. Shares of COLL have risen 3.1% year to date.
Earnings of Collegium Pharmaceutical missed estimates in three of the last four quarters and beat the mark on one occasion, the negative surprise being 57.6%, on average.